Upload
charise-ligores
View
217
Download
0
Embed Size (px)
Citation preview
8/13/2019 Tb and Leprosy
1/39
Tuberculosis
8/13/2019 Tb and Leprosy
2/39
8/13/2019 Tb and Leprosy
3/39
Infectious Agent
Mycobacterium tuberculosisandM. Africanumprimarily from humans, andM. bovisprimarily fromcattle.
8/13/2019 Tb and Leprosy
4/39
Mode of Transmission
Airborne droplet method through coughing, singingor sneezing.
Direct invasion through mucous membrane or
breaks in the skin may occur, but is extremely rare. Bovine tuberculosis result from exposure to
tuberculosis cattle, usually by ingestion ofunpasteurized milk or dairy products. Extra-
pulmonary tuberculosis, other than laryngeal, isgenerally not communicable, even if there is adraining sinus.
8/13/2019 Tb and Leprosy
5/39
Period of Communicability
8/13/2019 Tb and Leprosy
6/39
Susceptibility and Resistance
8/13/2019 Tb and Leprosy
7/39
Method of Control
8/13/2019 Tb and Leprosy
8/39
Preventive Measures
Prompt diagnosis and treatment of infectious cases BCG vaccination of newborn, infants and grade 1/ school
entrants Educate the public in mode of spread and methods of control
and the importance of early diagnosis. Improve social conditions, which increase the risk of
becoming infected. Such as overcrowding. Make available medical, laboratory and x- ray facilities for
eamination of patients, contacts and suspects, and facilitiesfor early treatment of cases and persons at high risk of
infection and beds for those needing hospitalization. Provide public health nursing and outreach services for home
supervision of patients to supervise therapy directly and toarrange for examination and prevent treatment of contacts.
8/13/2019 Tb and Leprosy
9/39
The National TuberculosisProgram
8/13/2019 Tb and Leprosy
10/39
Vision: A country where TB is no longer a public healthproblem
Mission: Ensure that TB DOTS services are available,accessible, and affordable to the communities in
collaboration with the LGUs and other partners
Goal: To reduce prevalence and mortality from TB byhalf by the year 2015 (Millennium Developmental
Goal)
8/13/2019 Tb and Leprosy
11/39
Targets:
Cure at least 85% of the sputum smear- positive TBpatient discovered
Detect at least 70% of the estimated new sputumsmear- positive TB cases
8/13/2019 Tb and Leprosy
12/39
NTP Objectives and Strategies
The NTPs four- pronged set of objectives calls
for improvement of access to and quality of services,enhancement of stakeholders health- seeking
behavior, sustainability of support for TB controlactivities, and strengthening management of TB
control services at all levels.
8/13/2019 Tb and Leprosy
13/39
Objective A: improve access to and quality of serviesprovided to TB patients, TB symptomatics, andcommunities by health care institutions and providers
8/13/2019 Tb and Leprosy
14/39
Strategies:
1. Enhance quality of TB diagnosis
2. Ensure TB patients treatment compliance
3. Ensure public and private health care providersadherence to the implementation of nationalstandards of care for TB patients.
4. Improve access to services through innovativeservice delivery mechanisms for patients living inchallenging areas (geographically isolatedcommunities with peace and order problem,culturally- different, and those in institutions likeprisons)
8/13/2019 Tb and Leprosy
15/39
Objective B: Enhance the health- seeking behaviors onTB by communities, especially the TB symptomatics
8/13/2019 Tb and Leprosy
16/39
Strategies:
Develop effective, appropriate, and culturally-responsive IEC/ communication materials.
Organize barangay advocacy groups
8/13/2019 Tb and Leprosy
17/39
Objective C: Increase and sustain support andfinancing for TB control activities
8/13/2019 Tb and Leprosy
18/39
Strategies:
Facilitate implementation of TB- DOTS Centercertification and accrediatation.
Build TB coalitions among different sectors.
Advocate for counterpart input from localgovernment units.
Mobilize/extend other resources to address programlimitations
8/13/2019 Tb and Leprosy
19/39
Objective D: Strengthen management (technical andoperational) of TB control services at all levels.
8/13/2019 Tb and Leprosy
20/39
Strategies:
Enhance managerial capability of all NTP programmanagers at all levels.
Establish an efficient data management system for
both public and private sectors. Implement a standardized recording and reporting
system.
Conduct regular monitoring and evaluation at all
levels. Advocate for political support through effective local
governance.
8/13/2019 Tb and Leprosy
21/39
Key Policies
Category Type of TB patient Treatment Regimen
8/13/2019 Tb and Leprosy
22/39
Category Type of TB patient Treatment RegimenIntensive phase Continuation Phase
I New smear- positive PTB New smear- negative PTB
with extensive parenchymallesions on CXR as assessed
by th TBDC EPTB Severe concomitant HIV
disease
2HRZE 4 HR
II Treatment failure Relapse Return after Default Other
2HRZE/ 1HRZE 5HRE
III New smear- negative PTBwith minimal parenchymallesions on CXR as assessedby the TBDC
2HRZE 4HR
IV Chronic (still smear- positiveafter supervised treatment) Refer to specialized facility or DOTS PlusCenter
Refer to provincial/ City NTP coordinator
8/13/2019 Tb and Leprosy
23/39
Body weight (kg) No. of tablets per dayIntensive Phase
(2 months)FDA (HRZE)
No. of tablets per dayContinuation Phase
(4 months)FDC- B (HR)
30- 37 2 238- 54 3 355- 70 4 4
>70 5 5
8/13/2019 Tb and Leprosy
24/39
Bodyweight
(kg)Intensive Phase Continuation Phase
First two months Third mo. FDC- B(HR) E400mg
FDC- A(HRZE) Streptomycin FDC- A(HRZE)
30- 37 2 0.75 g 2 2 138-54 3 0.75 g 3 3 255- 70 4 0.75 g 4 4 3
>70 5 0.75 g 5 5 3
8/13/2019 Tb and Leprosy
25/39
Anti- TB Drugs No. of tablets per dayIntensive Phase
(3 months)No. of tablets per dayContinuation Phase
(4 months)
Isoniazid (H) 1 1Rifampicin 1 1
Pyrazinamide (Z) 2Ethambutol (E) 2
8/13/2019 Tb and Leprosy
26/39
Anti- TB Drugs No. of tablets/vial perday
Intensive Phase
(3 months)
No. of tablets per dayContinuation Phase
(5 months)
First 2months 3
rdmonths
Isoniazid (H) 1 1 1Rifampicin (R) 1 1 1Pyrazinamide (Z) 2 2Ethambutol (E) 2 2 2Streptomycin (S) 1 vial/day*
8/13/2019 Tb and Leprosy
27/39
DOTS Strategy
DOTS is the internationally- recommended TB controlstrategy and combines five elements. The five elements arethe following: Sustained political commitment Access to quality- assured sputum microscopy Standardized short- course chemotherapy for all cases of
TB under proper case management conditions, includingdirect observation of treatment
Uninterrupted supply of quality- assured drugs
Recording and reporting system enabling outcomeassessment of all patients and assessment of overallprogram performance.
8/13/2019 Tb and Leprosy
28/39
Public Health Nursing Responsibility (Adult TB)
Together with other NTP staffworker, manage the procedures for case-finding activities
Assign and supervise a treatment partner for patient whi will undergoDOTS.
Supervise rural health midwives (RHMs) to ensure proper implementationof DOTS.
Maintain and update the TB Register Facilitate requisition and distribution of drugs and other NTP supplies. Provide continuous health education to all TB patients placed under
treatment and encourage family and community participation in TBcontrol.
In coordination with the physician, conduct training of health workers.
Prepare, analyse, and submit the quarterly reports to the Provincial HealthOffice or City Health Office.
8/13/2019 Tb and Leprosy
29/39
Leprosy
8/13/2019 Tb and Leprosy
30/39
Signs and Symptoms
1. Early Signs and Symptoms Change in skin color- either reddish or white
Loss of sensation on the skin lesion
Decrease/ loss of sweating and hair growth over thelesion
Thickened and/ or painful nerves
Muscle weakness or paralysis of extremities
Pain and redness of the eyes Nasal obstruction or bleeding
Ulcers that do not heal
8/13/2019 Tb and Leprosy
31/39
2. Late Signs and Symptoms
Loss of eyebrow- madarosis
Inability to close eyelids- lagophthalmos
Clawing of fingers and toes Contractures
Shrinking of the nose bridge
Enlargement of the breast in males or gynecomastia Chronic ulcers
8/13/2019 Tb and Leprosy
32/39
Infectious Agent
Mycobacterium leprae an acid fast, rod- shapedbacillus which can be detected by Silt Skin Smear(SSS)
8/13/2019 Tb and Leprosy
33/39
Method of Transmission
Airborne- inhalation of droplet spray from coughinand sneezing of untreated leprosy patient
Prolonged skin-to-skin contact
8/13/2019 Tb and Leprosy
34/39
Diagnosis of leprosy is currently based on clinical signsand symptoms especially if there is history of contact
with person with leprosy (PWL). Only in rare instances isthere really a need to use laboratory and otherinvestigation to confirm a diagnosis.
Silt Skin Smear (SSS) examination is an optionalprocedure. It is done only when clinical diagnosis isdoubtful. The main objective is to preventmisclassification and wrong treatment. A ready referralfacility must be recognized in the conduct of SSS
procedures. Susceptibility- Children especially twelve years and below are moresusceptible
8/13/2019 Tb and Leprosy
35/39
Prevention
Avoidance of prolonged skin-to-skin contactespecially with a lepromatous case
Children should avoid close contact with active,untreated leprosy case
BCG vaccination
Good Personal Hygiene
Adequate Nutrition
Health Education
8/13/2019 Tb and Leprosy
36/39
Leprosy Control Program
Vision: Empowered primary stakeholders inleprosy and eliminated leprosy as a public healthproblem by 2020
Mission: To ensure the provision of acomprehensive, integrated quality leprosy services atall levels of health care
Goal: To maintain and sustain the elimination
status
8/13/2019 Tb and Leprosy
37/39
The National Leprosy Control Program aims to:
Ensure the availability of adequate anti-leprosy drugs ormultiple drug therapy (MDT).
Prevent and reduce disabilities from leprosy by 35% throughRehabilitation and Prevention of Impairments andDisabilities (RPIOD) and Self Care.
Improve case detection and post-elimination surveillancesystem using the WHO protocol in selected LGUs. Integration of leprosy control with other health services at the
local level. Active participation of person affected by leprosy in leprosy
control and human dignity program in collaboration with theNational Program for Persons with Disability. Strengthen the collaboration with partners and other
stakeholders in the provision of quality leprosy services forsocio-economic mobilization and advocacy activities forleprosy.
8/13/2019 Tb and Leprosy
38/39
Public Health Responsibilities
a. Prevention
Health education of patients, families and thecommunity on the nature of the disease,
symptomatology and its transmission. Children whoare more susceptible to the disease should not beexposed to untreated lepromatous cases.
Advocate healthful living through proper nutrition,
adequate rest, sleep and good personal hygiene. BCG vaccination especially of infants and children.
8/13/2019 Tb and Leprosy
39/39
b. Casefinding Recognize early signs and symptoms of leprosy and refers
suspects to the RHU physician or skin clinic for diagnosis andtreatmen
Takes patient and family history and files up patient records Conducts epidemiological investigation and report findings to
MHO
Assists physician in physical examination of patients in theclinic/ home.
Assesses health of the family members and other householdcontacts. Performs/assists in examination of contacts
Integrates casefinding of leprosy case in other activities suchas MCH, EPI, inspection, examination of school children andother programs